Enocitabine

Enocitabine is a nucleoside analogue and antineoplastic agent that is used in cancer treatment. It is a cytidine analogue, which means it is structurally similar to the nucleoside cytidine. Enocitabine is used in the treatment of various types of cancer, including leukemia and lymphoma.

Mechanism of Action

Enocitabine works by inhibiting the synthesis of DNA in cancer cells, thereby preventing their growth and proliferation. It is incorporated into the DNA of cancer cells during the S phase of the cell cycle, causing DNA damage and leading to cell death.

Side Effects

Like all chemotherapy drugs, enocitabine can cause side effects. These may include nausea, vomiting, diarrhea, and myelosuppression, which is a decrease in the production of blood cells in the bone marrow. Other potential side effects include hair loss, fatigue, and infection due to a weakened immune system.

Contraindications

Enocitabine should not be used in patients with known hypersensitivity to the drug or any of its components. It should also be used with caution in patients with impaired kidney function or liver function, as these conditions can affect the metabolism and excretion of the drug.

Drug Interactions

Enocitabine may interact with other drugs, including other chemotherapy drugs, antiviral drugs, and certain antibiotics. These interactions can affect the effectiveness of enocitabine and increase the risk of side effects.

Dosage and Administration

The dosage of enocitabine is based on the patient's body surface area and the type of cancer being treated. It is usually administered intravenously over a period of 1 to 2 hours.

See Also

• Nucleoside analogue
• Antineoplastic agent
• Chemotherapy
• Cancer

Enocitabine Resources
Latest articles Most recent articles Ongoing trials	Wikipedia